{"generic":"Cosyntropin","drugs":["Cortrosyn","Cosyntropin","Cosyntropin"],"mono":{"0":{"id":"144350-s-0","title":"Generic Names","mono":"Cosyntropin"},"1":{"id":"144350-s-1","title":"Dosing and Indications","sub":{"0":{"id":"144350-s-1-4","title":"Adult Dosing","mono":"<ul><li>cosyntropin injection by Sandoz, Inc., should not to be given intramuscularly; however, there are cosyntropin products available from other manufacturers that may be given IM or IV<\/li><li>a solution of 0.25 milligram of cosyntropin is equivalent to corticotropin (ACTH) 25 USP units<\/li><li><b>Adrenal insufficiency, Standard-dose; Diagnosis:<\/b> Cortrosyn(TM) (Amphastar Pharmaceuticals, Inc), 0.25 to 0.75 mg IM or IV over 2 min, diluted in NS<\/li><li><b>Adrenal insufficiency, Standard-dose; Diagnosis:<\/b> Cosyntropin (Sandoz, Inc), 0.25 to 0.75 mg IV over 2 min, diluted in NS<\/li><li><b>Adrenal insufficiency, Standard-dose; Diagnosis:<\/b> IV infusion 0.04 mg\/hr over 6 hr, diluted in glucose or saline solutions<\/li><\/ul>"},"1":{"id":"144350-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>cosyntropin injection by Sandoz, Inc., should not to be given intramuscularly; however, there are cosyntropin products available from other manufacturers that may be given IM or IV<\/li><li>a solution of 0.25 milligram of cosyntropin is equivalent to corticotropin (ACTH) 25 USP units<\/li><li><b>Adrenal insufficiency, Standard-dose; Diagnosis:<\/b> (2 yr of age or less) Cortrosyn(TM) (Amphastar Pharmaceuticals, Inc), 0.125 mg IM or IV over 2 min, diluted in NS<\/li><li><b>Adrenal insufficiency, Standard-dose; Diagnosis:<\/b> (2 yr of age or less) Cosyntropin (Sandoz, Inc), 0.125 mg IV over 2 min, diluted in NS<\/li><li><b>Adrenal insufficiency, Standard-dose; Diagnosis:<\/b> (over 2 yr) Cortrosyn(TM) (Amphastar Pharmaceuticals, Inc), 0.25 to 0.75 mg IM or IV over 2 min, diluted in NS<\/li><li><b>Adrenal insufficiency, Standard-dose; Diagnosis:<\/b> (over 2 yr) Cosyntropin (Sandoz, Inc), 0.25 to 0.75 mg IV over 2 min, diluted in NS<\/li><\/ul>"},"3":{"id":"144350-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Adrenal insufficiency, Standard-dose; Diagnosis<br\/><b>Non-FDA Labeled Indications<\/b><ul><li>Adrenal insufficiency, Low-dose; Diagnosis<\/li><li>West syndrome<\/li><\/ul>"}}},"3":{"id":"144350-s-3","title":"Contraindications\/Warnings","sub":[{"id":"144350-s-3-9","title":"Contraindications","mono":"history of hypersensitivity to cosyntropin<br\/>"},{"id":"144350-s-3-10","title":"Precautions","mono":"hypersensitivity to natural ACTH<br\/>"},{"id":"144350-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"144350-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"144350-s-4","title":"Drug Interactions","sub":[{"id":"144350-s-4-13","title":"Contraindicated","mono":"<ul>Rotavirus Vaccine, Live (established)<\/ul>"},{"id":"144350-s-4-14","title":"Major","mono":"<ul><li>Bupropion (theoretical)<\/li><li>Itraconazole (probable)<\/li><\/ul>"},{"id":"144350-s-4-15","title":"Moderate","mono":"<ul><li>Balofloxacin (established)<\/li><li>Besifloxacin (established)<\/li><li>Ciprofloxacin (established)<\/li><li>Enoxacin (established)<\/li><li>Fleroxacin (established)<\/li><li>Flumequine (established)<\/li><li>Gatifloxacin (established)<\/li><li>Gemifloxacin (established)<\/li><li>Levofloxacin (established)<\/li><li>Licorice (probable)<\/li><li>Lomefloxacin (established)<\/li><li>Moxifloxacin (established)<\/li><li>Nadifloxacin (established)<\/li><li>Norfloxacin (established)<\/li><li>Ofloxacin (established)<\/li><li>Pazufloxacin (established)<\/li><li>Pefloxacin (established)<\/li><li>Prulifloxacin (established)<\/li><li>Rufloxacin (established)<\/li><li>Saiboku-To (probable)<\/li><li>Sparfloxacin (established)<\/li><li>Tosufloxacin (established)<\/li><\/ul>"}]},"5":{"id":"144350-s-5","title":"Adverse Effects","mono":"<b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Bradyarrhythmia, Hypertension, Tachycardia<\/li><li><b>Immunologic:<\/b>Anaphylaxis (rare), Hypersensitivity reaction (rare)<\/li><\/ul>"},"6":{"id":"144350-s-6","title":"Drug Name Info","sub":{"0":{"id":"144350-s-6-17","title":"US Trade Names","mono":"<ul><li>Cortrosyn<\/li><li>Cosyntropin<\/li><\/ul>"},"2":{"id":"144350-s-6-19","title":"Class","mono":"<ul><li>Diagnostic Agent<\/li><li>Diagnostic Agent, Adrenocortical Function<\/li><li>Pituitary Hormone, Anterior<\/li><\/ul>"},"3":{"id":"144350-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"144350-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"144350-s-7","title":"Mechanism Of Action","mono":"<ul><li>Systemic: Cosyntropin combines with a specific receptor in the adrenal cell plasma membrane and, in patients with normal adrenocortical function, stimulates the initial reaction involved in the synthesis of adrenal steroids (including cortisol, cortisone, weak androgenic substances, and a limited quantity of aldosterone) from cholesterol by increasing the quantity of the substrate within the mitochondria. Cosyntropin does not significantly increase plasma cortisol concentration in patients with primary or secondary adrenocortical insufficiency. <\/li><li>Cosyntropin has less immunogenic activity than ACTH because the amino acid sequence having most of the antigenic activity of ACTH, i.e., amino acids 25-39, is not present in cosyntropin. <\/li><\/ul>"},"9":{"id":"144350-s-9","title":"Administration","mono":"<ul><li><b>Intramuscular<\/b><br\/>(Cortrosyn(TM), Amphastar Pharmaceuticals, Inc) reconstitute with 1 mL NS<br\/><\/li><li><b>Intravenous<\/b><br\/><ul><li>(injection) dilute in 2 to 5 mL of NS, inject over 2 min<\/li><li>(infusion) dilute in glucose or NS; infuse 40 mcg\/hr over 6 hr<\/li><\/ul><\/li><\/ul>"},"10":{"id":"144350-s-10","title":"Monitoring","mono":"adrenal response via plasma cortisol levels or urinary steroid excretion (before and after infusion) <br\/>"},"11":{"id":"144350-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/><ul><li>Injection Powder for Solution: 0.25 MG<\/li><li>Intravenous Solution: 0.25 MG\/ML<\/li><\/ul><\/li><li><b>Cortrosyn<\/b><br\/>Injection Powder for Solution: 0.25 MG<br\/><\/li><li><b>Novaplus Cosyntropin<\/b><br\/>Injection Powder for Solution: 0.25 MG<br\/><\/li><\/ul>"},"13":{"id":"144350-s-13","title":"Clinical Teaching","mono":"This drug may cause arrhythmias, edema, or dizziness.<br\/>"}}}